Use of a Polymer Additive To Enhance Impurity Rejection in the Crystallization of a Pharmaceutical Compound

The control of impurity content in active pharmaceutical ingredients is of utmost importance for the pharmaceutical industry. While crystallization is oftentimes used as an efficient and cost-effective means of achieving this purification, structurally similar impurities can be very difficult to separate via crystallization. The impact of nonadsorbing polymers on the crystallization of the compound of interest can be leveraged to enhance the purification of pharmaceutical molecules. Here we discuss a case study in which an impurity formed in a pilot plant batch at a level of 3% could not be adequately rejected using conventional crystallization processes. We used a polymer additive to modify the crystallization to enhance impurity rejection. The process was implemented on scale to successfully deliver the product with less than 0.1% of the impurity. We explain the observed influence of the polymer additive on the crystallization of the product by carrying out additional investigations and considering the ...

[1]  O. Shirai,et al.  Inhibition of crystal nucleation and growth by water-soluble polymers and its impact on the supersaturation profiles of amorphous drugs. , 2013, Journal of pharmaceutical sciences.

[2]  Lian Yu,et al.  Stability of Amorphous Pharmaceutical Solids: Crystal Growth Mechanisms and Effect of Polymer Additives , 2012, The AAPS Journal.

[3]  Lynne S. Taylor,et al.  Understanding the Behavior of Amorphous Pharmaceutical Systems during Dissolution , 2010, Pharmaceutical Research.

[4]  Edward L. Paul,et al.  Crystallization of Organic Compounds , 2009 .

[5]  Venkateswarlu Bhamidi,et al.  Beneficial effect of solubility enhancers on protein crystal nucleation and growth. , 2009, Langmuir : the ACS journal of surfaces and colloids.

[6]  Qingmei Ye,et al.  Identification of Critical Process Impurities and Their Impact on Process Research and Development , 2008 .

[7]  Jiben Roy,et al.  Pharmaceutical impurities—A mini-review , 2002, AAPS PharmSciTech.

[8]  S. Ahuja.  Assuring quality of drugs by monitoring impurities. , 2007, Advanced drug delivery reviews.

[9]  C. Zukoski,et al.  Determination of Critical Supersaturation from Microdroplet Evaporation Experiments , 2006 .

[10]  Kinam Park,et al.  Study on the interactions between polyvinylpyrrolidone (PVP) and acetaminophen crystals: partial dissolution pattern change. , 2005, Journal of pharmaceutical sciences.

[11]  G. Kwon,et al.  Amphiphilic block copolymer as a crystal habit modifier , 2005 .

[12]  F. Sadeghi,et al.  Increasing the Aqueous Solubility of Acetaminophen in the Presence of Polyvinylpyrrolidone and Investigation of the Mechanisms Involved , 2003, Drug development and industrial pharmacy.

[13]  Charles F. Zukoski,et al.  Nanoparticle Crystal Nucleation: Influence of Solution Conditions , 2002 .

[14]  J Hadgraft,et al.  Crystallization of hydrocortisone acetate: influence of polymers. , 2001, International journal of pharmaceutics.

[15]  K. Kachrimanis,et al.  Crystallisation conditions and physicomechanical properties of ibuprofen–Eudragit® S100 spherical crystal agglomerates prepared by the solvent-change technique , 1998 .

[16]  M. Spring,et al.  STUDIES ON PARACETAMOL CRYSTALS PRODUCED BY GROWTH IN AQUEOUS SOLUTIONS , 1994 .

[17]  J. Christoffersen,et al.  Relation between interfacial surface tension of electrolyte crystals in aqueous suspension and their solubility; a simple derivation based on surface nucleation , 1991 .

[18]  R. Kumar,et al.  Enhanced dissolution and absorption of trimethoprim from coprecipitates with polyethylene glycols and polyvinylpyrrolidone , 1991 .

[19]  D. E. Cadwallader,et al.  Effect of macromolecules on aqueous solubility of cholesterol and hormone drugs. , 1981, Journal of pharmaceutical sciences.